On April 29, 2024, the U.S. Food and Drug Administration (FDA) granted traditional approval to tisotumab vedotin-tftv (Tivdak®) for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Tisotumab vedotin-tftv previously received accelerated approval for the indication.
The Cancer Equity Leaders is a diverse team of premier cancer research leaders working under the National Cancer Institute (NCI) Center to Reduce Cancer Health Disparities. NCI announced the group and its members in an April 2024 blog post.
Lifting the veil on prostate cancer and sharing lifesaving information, former National Institutes of Health (NIH) Director Francis S. Collins, MD, PhD, revealed in April 2024 that his active surveillance, slow-growing prostate cancer had advanced to a Gleason score of 9. Collins made the announcement in a Washington Post perspective piece in which he accounted his experience from both a patient and clinician lens.
Remote verification methods through virtual care nurse models and telehealth technologies have merit, but the evidence is inadequate to determine safety or efficacy, according to the latest findings from a team of ONS members and staff that were published in the Clinical Journal of Oncology Nursing.
On April 23, 2024, the U.S. Food and Drug Administration (FDA) approved lutetium Lu 177 dotatate (Lutathera®) for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors. FDA approved lutetium Lu 177 dotatate for the indication for adults in 2018.
On April 23, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tovorafenib (Ojemda™) for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement or BRAF V600 variant.
In stark contrast to a nationwide decline, cervical cancer incidence and mortality rates are increasing in low-income U.S. counties, researchers reported in the International Journal of Cancer.
On April 22, 2024, the U.S. Food and Drug Administration (FDA) approved nogapendekin alfa inbakicept-pmln (Anktiva®) with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-unresponsive non–muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.
The first innovation in stem cell mobilization for multiple myeloma in a decade, motixafortide (Aphexda™) received U.S. Food and Drug Administration approval on September 11, 2023. The drug’s clinical trial demonstrated that one dose of motixafortide plus filgrastim enabled a majority of patients to achieve the collection goal of at least six million hematopoietic stem cells.
As an oncology nursing trailblazer, ONS Past President Judi L. Johnson, PhD, RN, FAAN, dedicated her career to guiding cancer education, patient-centered care, and oncology nursing excellence. On Saturday, April 20, 2024, Johnson passed away, leaving a far-reaching legacy on the profession and patients around the world.